VIDEO: Securing the Drug Supply Chain

Demystifying PBMs, Their Role in the Drug Supply Chain

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Brian Nowosielski;Antonio Ciaccia

Tremfya Demonstrates Sustained Response Up to 92 Weeks

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Scripted for Her: Helping Patients Choose Contraceptive Methods

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Jasmine Cutler, PharmD, CPh

Bemnifosbuvir, Ruzasvir Regimen Shows Strong Efficacy as HCV Treatment

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

Related Content

Demystifying PBMs, Their Role in the Drug Supply Chain

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Brian Nowosielski;Antonio Ciaccia

Tremfya Demonstrates Sustained Response Up to 92 Weeks

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Scripted for Her: Helping Patients Choose Contraceptive Methods

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Jasmine Cutler, PharmD, CPh

Bemnifosbuvir, Ruzasvir Regimen Shows Strong Efficacy as HCV Treatment

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.